Halozyme Statistics
Halozyme (RV7) Stock Statistics & Valuation Metrics
Total Valuation
Halozyme has a market cap or net worth of CHF 9.59B. The enterprise value is CHF 15.71B.
- Market Cap
- CHF 9.59B
- Enterprise Value
- CHF 15.71B
Share Statistics
Halozyme has 114,010,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 114,010,000
- Owned by Insiders
- 0.92%
- Owned by Institutions
- 93.29%
Financial Efficiency
Halozyme’s return on equity (ROE) is 6.49 and return on invested capital (ROIC) is 23.20%.
- Return on Equity (ROE)
- 6.49
- Return on Assets (ROA)
- 0.13
- Return on Invested Capital (ROIC)
- 23.20%
- Return on Capital Employed (ROCE)
- 0.34
- Revenue Per Employee
- 3.30M
- Profits Per Employee
- 749.15K
- Employee Count
- 423
- Asset Turnover
- 0.55
- Inventory Turnover
- 1.30
Valuation Ratios
The current PE Ratio of Halozyme is 23.87. Halozyme’s PEG ratio is -1.69.
- PE Ratio
- 23.87
- PS Ratio
- 6.34
- PB Ratio
- -206.56
- Price to FCF
- 12.90
- Price to Operating Cash Flow
- 12.70
- PEG Ratio
- -1.69
Income Statement
In the last 12 months, Halozyme had revenue of 1.40B and earned 316.89M in profits. Earnings per share was 2.64.
- Revenue
- 1.40B
- Gross Profit
- 1.17B
- Operating Income
- 802.59M
- Pretax Income
- 466.88M
- Net Income
- 316.89M
- EBITDA
- 573.05M
- Earnings Per Share (EPS)
- 2.64
Cash Flow
In the last 12 months, operating cash flow was 898.27M and capital expenditures -12.39M, giving a free cash flow of 885.88M billion.
- Operating Cash Flow
- 898.27M
- Free Cash Flow
- 885.88M
- Free Cash Flow per Share
- 7.78
Dividends & Yields
Halozyme pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 7.75%
- Earnings Yield
- 4.25%
Stock Price Statistics
- Beta
- 1.41
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 101.90
- 200-Day Moving Average
- 101.90
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- 15
Important Dates
Halozyme upcoming earnings date is Feb 23, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Feb 23, 2027
- Ex-Dividend Date
- ―
Financial Position
Halozyme as a current ratio of 4.66, with Debt / Equity ratio of 4389.38%
- Current Ratio
- 4.66
- Quick Ratio
- 3.66
- Debt to Market Cap
- 0.27
- Net Debt to EBITDA
- 3.51
- Interest Coverage Ratio
- 44.28
Taxes
In the past 12 months, Halozyme has paid 149.99M in taxes.
- Income Tax
- 149.99M
- Effective Tax Rate
- 0.32
Enterprise Valuation
Halozyme EV to EBITDA ratio is 16.95, with an EV/FCF ratio of 15.41.
- EV to Sales
- 7.57
- EV to EBITDA
- 16.95
- EV to Free Cash Flow
- 15.41
- EV to Operating Cash Flow
- 15.20
Balance Sheet
Halozyme has CHF 1.07B in cash and marketable securities with CHF 3.25B in debt, giving a net cash position of -CHF 2.18B billion.
- Cash & Marketable Securities
- CHF 1.07B
- Total Debt
- CHF 3.25B
- Net Cash
- -CHF 2.18B
- Net Cash Per Share
- -CHF 19.09
- Tangible Book Value Per Share
- -CHF 13.44
Margins
Gross margin is 82.27%, with operating margin of 55.91%, and net profit margin of 26.93%.
- Gross Margin
- 82.27%
- Operating Margin
- 55.91%
- Pretax Margin
- 36.34%
- Net Profit Margin
- 26.93%
- EBITDA Margin
- 44.70%
- EBIT Margin
- 37.56%
Analyst Forecast
The average price target for Halozyme is CHF 96.48, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- CHF 96.48
- Price Target Upside
- 5.32% Downside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 7
- Revenue Growth Forecast
- 36.53%
- EPS Growth Forecast
- -19.06%
Scores
- Smart Score
- 7
- AI Score
- ―
